2018 法国慢性粒细胞白血病研究组实践建议:酪氨酸激酶抑制剂治疗慢性粒细胞白血病的停药

2018-05-03 国外血液科相关专家小组 Cancer. 2018 May 3.

酪氨酸激酶抑制剂(TKI)治疗慢性粒细胞白血病的终极目标是或得深层分子学反应,即无治疗缓解。来自法国慢性粒细胞白血病研究组的20位专家共同提出了关于TKI治疗慢性粒细胞白血病的停药建议。

中文标题:

2018 法国慢性粒细胞白血病研究组实践建议:酪氨酸激酶抑制剂治疗慢性粒细胞白血病的停药

英文标题:

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

发布日期:

2018-05-03

简要介绍:

酪氨酸激酶抑制剂(TKI)治疗慢性粒细胞白血病的终极目标是或得深层分子学反应,即无治疗缓解。来自法国慢性粒细胞白血病研究组的20位专家共同提出了关于TKI治疗慢性粒细胞白血病的停药建议。 

拓展指南:慢性粒细胞白血病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018 法国慢性粒细胞白血病研究组实践建议:酪氨酸激酶抑制剂治疗慢性粒细胞白血病的停药)] GetToolGuiderByIdResponse(projectId=1, id=5c8f51c00158888f, title=2018 法国慢性粒细胞白血病研究组实践建议:酪氨酸激酶抑制剂治疗慢性粒细胞白血病的停药, enTitle=Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group., guiderFrom=Cancer. 2018 May 3., authorId=null, author=, summary=酪氨酸激酶抑制剂(TKI)治疗慢性粒细胞白血病的终极目标是或得深层分子学反应,即无治疗缓解。来自法国慢性粒细胞白血病研究组的20位专家共同提出了关于TKI治疗慢性粒细胞白血病的停药建议。 , cover=, journalId=null, articlesId=null, associationId=971, associationName=国外血液科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Thu May 03 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>酪氨酸激酶抑制剂(TKI)治疗慢性粒细胞白血病的终极目标是或得深层分子学反应,即无治疗缓解。来自法国慢性粒细胞白血病研究组的20位专家共同提出了关于TKI治疗慢性粒细胞白血病的停药建议。 </div> <div><br> </div>拓展指南:<strong>与<font color="red">慢性粒细胞白血病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=c479a1c0015039a6" title="2017 日本造血和淋巴组织肿瘤指南:慢性粒细胞白血病/骨髓增生性肿瘤" target="_blank">2017 日本造血和淋巴组织肿瘤指南:慢性粒细胞白血病/骨髓增生性肿瘤</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E6%85%A2%E6%80%A7%E7%B2%92%E7%BB%86%E8%83%9E%E7%99%BD%E8%A1%80%E7%97%85" target="_blank">有关慢性粒细胞白血病更多指南</a></ul>, tagList=[TagDto(tagId=7635, tagName=酪氨酸激酶抑制剂), TagDto(tagId=750, tagName=慢性粒细胞白血病), TagDto(tagId=6229, tagName=停药)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7967, appHits=146, showAppHits=0, pcHits=6217, showPcHits=3415, likes=120, shares=7, comments=2, approvalStatus=1, publishedTime=Tue May 08 21:11:59 CST 2018, publishedTimeString=2018-05-03, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue May 08 21:11:59 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 20:18:28 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 法国慢性粒细胞白血病研究组实践建议:酪氨酸激酶抑制剂治疗慢性粒细胞白血病的停药)])
2018 法国慢性粒细胞白血病研究组实践建议:酪氨酸激酶抑制剂治疗慢性粒细胞白血病的停药
下载请点击:
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=313798, encodeId=a75e313e989b, content=有中文版就好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJX0s1vNmBS8mWcqJpsuqbcaYs3BgicQOXku4noBN3ic7N48OEjz6cat787CeYic1Wrt1e8mr30hgWFw/132, createdBy=08432344591, createdName=十二呀十二, createdTime=Thu May 10 10:18:10 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313797, encodeId=a1c5313e97b6, content=要是, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJX0s1vNmBS8mWcqJpsuqbcaYs3BgicQOXku4noBN3ic7N48OEjz6cat787CeYic1Wrt1e8mr30hgWFw/132, createdBy=08432344591, createdName=十二呀十二, createdTime=Thu May 10 10:17:57 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-10 十二呀十二

    有中文版就好了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=313798, encodeId=a75e313e989b, content=有中文版就好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJX0s1vNmBS8mWcqJpsuqbcaYs3BgicQOXku4noBN3ic7N48OEjz6cat787CeYic1Wrt1e8mr30hgWFw/132, createdBy=08432344591, createdName=十二呀十二, createdTime=Thu May 10 10:18:10 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313797, encodeId=a1c5313e97b6, content=要是, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJX0s1vNmBS8mWcqJpsuqbcaYs3BgicQOXku4noBN3ic7N48OEjz6cat787CeYic1Wrt1e8mr30hgWFw/132, createdBy=08432344591, createdName=十二呀十二, createdTime=Thu May 10 10:17:57 CST 2018, time=2018-05-10, status=1, ipAttribution=)]
    2018-05-10 十二呀十二

    要是

    0